@article {Khan2020.11.18.20233510, author = {Imran Khan and Robert E. Minto and Christine Kelley-Patteson and Bruce W. Van Natta and Colby R. Neumann and Lily J. Suh and Kanhaiya Singh and Mary Lester and R Jason VonDerHaar and Gayle M. Gordillo and Aladdin H. Hassanein and Chandan K. Sen and Marshall E. Kadin and Mithun Sinha}, title = {Biofilm Derived Oxylipin Mediated Autoimmune Response in Breast Implant Subjects}, elocation-id = {2020.11.18.20233510}, year = {2020}, doi = {10.1101/2020.11.18.20233510}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Over 10 million women worldwide have breast implants for breast cancer/prophylactic reconstruction or cosmetic augmentation. In recent years, a number of patients have described a constellation of symptoms that are believed to be related to their breast implants. This constellation of symptoms has been named Breast Implant Illness (BII). The symptoms described include chronic fatigue, joint pain, muscle pain and a host of other manifestations often associated with autoimmune illnesses. In this work, we report that bacterial biofilm is associated with BII. We postulate that the pathogenesis of BII is mediated via a host-pathogen interaction whereby the biofilm bacteria Staphylococcus epidermidis interacts with breast lipids to form the oxylipin 10-HOME. The oxylipin 10-HOME was found to activate CD4+ T cells to Th1 subtype. An increased abundance of CD4+Th1 was observed in the breast tissue of BII subjects. The identification of a mechanism of immune activation associated with BII via a biofilm enabled pathway provides insight into the pathogenesis for implant-associated autoimmune symptoms.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis is a retrospective observational study performed on surgically discarded specimens from the subjects.Funding StatementThis work was supported by Aesthetic Surgery Education and Research Foundation (ASERF) grant to MS, Department of Defense PR200435, and American Association of Plastic Surgeons grants to AHH, the US National Institutes of Health grants NIH NR015676, U01DK119099 to GG and CKS; NIH R01GM108014, R01NS042617, R01DK125835 to CKS.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All human studies were approved by The Indiana University School of Medicine Institutional Review Board. Declaration of Helsinki protocols was followed, and patients gave their written informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are available from the corresponding author upon reasonable request.}, URL = {https://www.medrxiv.org/content/early/2020/11/20/2020.11.18.20233510}, eprint = {https://www.medrxiv.org/content/early/2020/11/20/2020.11.18.20233510.full.pdf}, journal = {medRxiv} }